TD Waterhouse Canada Inc. Sells 2,552 Shares of Stryker Corporation $SYK

TD Waterhouse Canada Inc. decreased its holdings in shares of Stryker Corporation (NYSE:SYK) by 1.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 171,354 shares of the medical technology company’s stock after selling 2,552 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Stryker were worth $60,217,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Clark Asset Management LLC bought a new stake in Stryker during the 4th quarter valued at $223,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Stryker by 2.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 99,756 shares of the medical technology company’s stock valued at $35,061,000 after acquiring an additional 2,613 shares during the period. Krilogy Financial LLC raised its holdings in Stryker by 81.1% during the 4th quarter. Krilogy Financial LLC now owns 1,166 shares of the medical technology company’s stock valued at $416,000 after acquiring an additional 522 shares during the period. Earned Wealth Advisors LLC bought a new stake in Stryker during the 4th quarter valued at $867,000. Finally, Elevated Capital Advisors LLC bought a new stake in Stryker during the 4th quarter valued at $66,000. Institutional investors own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 4.60% of the company’s stock.

Stryker Trading Down 0.1%

Stryker stock opened at $343.09 on Monday. The stock has a market cap of $131.40 billion, a P/E ratio of 40.84, a PEG ratio of 2.01 and a beta of 0.92. Stryker Corporation has a fifty-two week low of $319.32 and a fifty-two week high of $404.87. The firm’s fifty day moving average price is $352.97 and its 200-day moving average price is $359.51. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.07. The firm had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.01 earnings per share. Equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s payout ratio is 41.90%.

Analysts Set New Price Targets

SYK has been the topic of a number of analyst reports. Jefferies Financial Group reissued a “buy” rating and set a $465.00 target price on shares of Stryker in a report on Wednesday, March 4th. Robert W. Baird set a $437.00 target price on shares of Stryker in a report on Friday, January 30th. Leerink Partners started coverage on shares of Stryker in a report on Monday, April 13th. They issued an “outperform” rating and a $410.00 price target on the stock. William Blair reaffirmed an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Stryker in a report on Monday, December 22nd. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $421.11.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.